Lv1
36 积分 2024-03-07 加入
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study
2天前
已完结
Radical abdominal trachelectomy for cervical malignancies: surgical, oncological and fertility outcomes in 62 patients
24天前
已完结
Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for newly-diagnosed and platinum-sensitive recurrent ovarian cancer with BRCA mutational status: a systematic review and network meta-analysis
1个月前
已完结
Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial
1个月前
已完结
Accelerating the integration of China into the global development of innovative anticancer drugs
2个月前
已完结
Challenges for Chinese innovative cancer drugs in going global: insights from multiregional clinical trials
2个月前
已完结
PARP Inhibitors Rechallenge in Patients With Recurrent Ovarian Cancer: A Multicentre Real-World Study in China
2个月前
已完结
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial
2个月前
已完结
PARP Inhibitors Rechallenge in Patients With Recurrent Ovarian Cancer: A Multicentre Real‐World Study in China
2个月前
已完结
(ENCORE) Rinatabart sesutecan for patients with advanced ovarian cancer: Results from dose expansion cohort B1 of phase I/II study
3个月前
已完结